MALVERN, Pa., May 4, 2011 /PRNewswire/ — Auxilium
Pharmaceuticals, Inc. (Nasdaq:
AUXL) today announced that executive management will
participate in the Bank of America Merrill Lynch 2011 Health Care
Conference during May 10-12, 2011 at the Encore at Wynn Las Vegas.
Mr. Armando Anido, Chief Executive Officer and President, is
scheduled to present an overview of the Company and its product
pipeline at 5:20 p.m. ET on Wednesday, May 11, 2011.
(Logo:
http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)
To listen to the audio web cast of the presentation during or
after the event, please visit: http://www.auxilium.com. The
replay will be available for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical
company with a focus on developing and marketing products to
predominantly specialist audiences, such as urologists,
endocrinologists, certain targeted primary care physicians, hand
surgeons, subsets of orthopedic, general, and plastic surgeons who
focus on the hand, and rheumatologists. Auxilium markets
XIAFLEX® (collagenase clostridium histolyticum) for the
treatment of adult Dupuytren’s contracture patients with a palpable
cord and Testim® 1%, a testosterone gel, for the topical
treatment of hypogonadism in the U.S. Pfizer Inc. has marketing
rights for XIAPEX® (the EU tradename for collagenase
clostridium histolyticum) in 46 countries in Eurasia and Asahi
Kasei Pharma Corporation has development and commercial rights for
XIAFLEX in Japan. Ferring International Center S.A. markets Testim
in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium
has two projects in clinical development. XIAFLEX is in phase III
of development for the treatment of Peyronie’s disease and is in
phase II of development for treatment of Froz
‘/>”/>
